South Africa proposes limiting drug patent extensions

04/23/2013 | PharmaLive.com

South Africa has announced plans to limit the ability of drug firms to win patent extensions for brand-name drugs by changing or modifying them in minor ways. Critics allege that such extensions block patients from receiving cheaper and more affordable versions of life-saving medications for such conditions as HIV/AIDS. The South African move comes barely a month after India rejected a patent extension request from Novartis for its best-selling Gleevec cancer treatment.

View Full Article in:

PharmaLive.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ